SOCS-1 can suppress CD3ζ- and Syk-mediated NF-AT activation in a non-lymphoid cell line  by Matsuda, Tadashi et al.
SOCS-1 can suppress CD3j- and Syk-mediated NF-AT activation in a
non-lymphoid cell line
Tadashi Matsudaa;*, Tetsuya Yamamotoa, Hiroyuki Kishia, Akihiko Yoshimurab,
Atsushi Muraguchia
aDepartment of Immunology, Faculty of Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930-0194, Japan
bInstitute of Life Science, Kurume University, 2432-3 Aikawa-machi, Kurume 839-0861, Japan
Received 25 February 2000
Edited by Giulio Superti-Furga
Abstract To elucidate T cell antigen receptor (TCR) signaling
leading to activation nuclear factor of activated T cells (NF-AT),
we reconstituted TCR signaling to activate NF-AT in a non-
lymphoid cell line, 293T. We demonstrated that co-expression of
CD8/j and Syk were necessary for NF-AT activation in 293T.
This NF-AT response was completely inhibited by the addition of
cyclosporin A or FK506, but markedly enhanced by the
additional expression of Tec protein tyrosine kinase. We also
show that the cytokine signaling suppressor, suppressor of
cytokine signaling 1, potently inhibited this response by
interacting with Syk and immunoreceptor tyrosine-based activa-
tion motifs in CD8/j. These results imply that this novel system
may provide a useful tool to delineate or identify the regulatory
molecules for CD3j/Syk-mediated NF-AT activation.
z 2000 Federation of European Biochemical Societies.
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1. Introduction
Multiple protein tyrosine kinases (PTKs) are required to
convey signals from T cell antigen receptors (TCRs). Previous
biochemical studies have shown that TCR signaling events
involve the activation of two families of PTKs: Src PTKs
(Lck and Fyn), and Syk/ZAP70 PTKs. The Src PTKs phos-
phorylate the two conserved tyrosine residues in the immu-
noreceptor tyrosine-based activation motif (ITAM), which is
present in each of the TCR signaling units. The phosphory-
lated ITAMs mediate the interaction of Syk/ZAP70 PTKs
with the receptor, amplifying the TCR-triggered signal by
phosphorylating additional intracellular substrates including
phospholipase C-Q (PLC-Q), Cbl, Vav, LAT, and SLP76
[1,2]. Tyrosine phosphorylation of PLC-Q induces its enzy-
matic activity, leading to the activation of the inositol phos-
pholipid pathway, followed by activation of protein kinase C
and increase in intracellular calcium [2]. Calcineurin, a Ca2-
activated phosphatase, is then activated and induces nuclear
factor of activated T cell (NF-AT) activation, which ¢nally
activates transcription of the interleukin-2 (IL-2) gene [3].
Recent studies showed that Syk, but not ZAP70, alone
stimulated tyrosine phosphorylation of both a chimeric j mol-
ecule (Tjj) in transiently transfected COS-1 cells and a j-
derived ITAM peptide in vitro [4]. The potential of Syk to
promote ITAM phosphorylation may allow TCR-mediated
signals to proceed in the absence of optimal activation of
Src family kinases. This may be important for thymocytes
bearing low levels of antigen receptors, for naive T cells,
and for T cells lacking the appropriate co-receptor molecules
(such as QN T cells) in which Syk expression has been docu-
mented [5,6].
More recently, members of the SOCS (suppressor of cyto-
kine signaling) family have been proposed as negative regu-
lators of cytokine signaling [7^9]. SOCS-1 inhibits IL-6-in-
duced phosphorylation of gp130, JAK2, and STAT3, and
the subsequent di¡erentiation of M1 cells into macrophages.
In mice, SOCS-1 is constitutively expressed in the thymus, and
the thymus in SOCS-1-de¢cient mice was markedly reduced in
size due to the unregulated activation of thymocytes [10,11],
suggesting that SOCS-1 is involved in the activation and de-
velopment of thymocytes. SOCS-1 has also been shown to
bind Tec and suppress Tec’s kinase activity [12].
Here, we provide a novel system to explore the TCR signal-
ing pathway using a non-lymphoid cell line, 293T, which is
commonly used for e⁄cient expression of various vectors. We
expressed CD8/j chimeric molecules and various PTKs in
293T, and tyrosine phosphorylation of various substrates as
well as NF-AT activity was determined. In this system, Syk,
but not ZAP70, stimulated the NF-AT-mediated transcrip-
tional response in the presence of CD8/j chimeric molecules.
We show that this NF-AT activation was mediated by PLC-Q1
and completely inhibited by inhibitors of the calcineurin path-
way, cyclosporin A (CsA) and FK506. We also show that the
additional expression of Tec PTK markedly enhanced the NF-
AT activation induced by CD8/j and Syk. Finally we show
that one member of the SOCS family, SOCS-1, inhibited this
NF-AT activation by directly binding to both Syk and
ITAMs of CD3j.
2. Materials and methods
2.1. Cell lines and reagents
A human embryonic kidney cell line, 293T, was maintained in Dul-
becco’s modi¢ed Eagle’s medium supplemented with 10% fetal calf
serum. pTfneo-CD8/j, pLGP3-mNFAT1-C, pNFAT3-Luc, porcine
Syk in pEFBOS, human ZAP70 in pME18S, human Lck in pCLS,
Tec in pSRK were kindly provided by Dr. A. Weiss (University of
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
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California, San Francisco, CA, USA), Dr. A. Rao (Harvard Medical
School, Boston, MA, USA), Dr. T. Kurosaki (Kansai Medical Uni-
versity, Moriguchi, Japan), Dr. T. Saito (Chiba University, Chiba,
Japan), Dr. M. Okada (Osaka University, Osaka, Japan) and Dr.
H. Mano (Jichi Medical School, Tochigi, Japan), respectively.
FK506 and CsA were kind gifts from Fujisawa (Osaka, Japan) and
Sandoz (Tokyo, Japan), respectively.
2.2. Antibodies
Monoclonal anti-human CD8 (3B5) was purchased from Caltag
Laboratories, Burlingame, CA, USA. Anti-ZAP70 was purchased
from Transduction Laboratories, Lexington, KY, USA. Anti-human
CD3j, anti-PLC-Q1, anti-Vav, and anti-Cbl were purchased from San-
ta Cruz Biotechnology (Santa Cruz, CA, USA). Anti-phosphotyrosine
monoclonal antibody (mAb) 4G10 was purchased from Upstate Bio-
technology (Lake Placid, NY, USA). Anti-Myc mAb 9E10 was pur-
chased from Boehringer Mannheim, Tokyo, Japan. Anti-porcine Syk
was generously supplied by Dr. Y. Minami (Kobe University, Kobe,
Japan). Anti-Lck antibody was kindly provided by Dr. M. Okada
(Osaka University, Osaka, Japan).
2.3. Transfections and luciferase assay
293T cells were plated in 6-cm dishes or in 10-cm dishes and trans-
fected by the standard calcium precipitation protocol. The cells were
harvested 48 h after transfection and lysed in 200 Wl of PicaGene
Reporter Lysis Bu¡er (Toyo Ink, Tokyo, Japan) and assayed for lu-
ciferase and L-galactosidase activities according to the manufacturer’s
instructions. Luciferase activities were normalized to the L-galactosi-
dase activities. Three or more independent experiments were carried
out.
2.4. Immunoprecipitation and immunoblotting
The transfected 293T cells were lysed in lysis bu¡er (50 mM Tris^
HCl, pH 7.4, 0.15 M NaCl, containing 1% NP-40, 1 mM sodium
orthovanadate, 1 mM phenylmethylsulfonyl £uoride and 10 Wg/ml
each of aprotinin, pepstatin and leupeptin).
The immunoprecipitates from cell lysates were resolved on 5^20%
SDS^PAGE and transferred to Immobilon (Millipore, Bedford, MA,
USA). The Immobilon ¢lters were then immunoblotted with each
antibody. Immunoreactive proteins were visualized using an enhanced
Fig. 1. Tyrosine phosphorylation of CD8/j and NF-AT activation in 293T cells. A: 293T cells in 10-cm dishes were transfected with each PTK
expression construct (5 Wg) and CD8/j (10 Wg) by the calcium precipitation method. After 48 h, the cells were lysed and CD8/j was immuno-
precipitated with anti-CD8 mAb. Phosphotyrosine-containing proteins were detected by immunoblotting with the anti-phosphotyrosine antibody
4G10 (upper panel). The blot was stripped and reprobed with anti-CD3j (lower panel). Expression of the appropriate proteins was con¢rmed
by immunoblotting of total cell lysates with antibody against each PTK (data not shown). Molecular weight markers on the left are in kilodal-
tons. The results shown here are representative of at least three independent experiments. B: 293T cells in 6-cm dishes were transfected with
each PTK expression construct (0.5 Wg), CD8/j (1.5 Wg), NF-ATc (1 Wg), NF-AT-Luc reporter (1 Wg) and 0.5 Wg of pSRK-LacZ (L-gal). 48 h
after transfection, cells were harvested and luciferase activity was determined. C: 293T cells in 6-cm dishes were transfected with increasing
amounts of CD8/j or Syk (Wg DNA) together with NF-ATc, NF-AT-Luc and L-gal. 48 h after transfection, cells were harvested and luciferase
activity was determined. The results shown here are representative of at least three independent experiments.
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chemiluminescence detection system (Amersham Pharmacia Biotech,
Tokyo, Japan).
2.5. In vitro binding assay
Peptide and phosphopeptides were kindly provided by Dr. J.N. Ihle
(St. Jude Children’s Research Hospital, Memphis, TN, USA) and
coupled to CNBr-activated Sepharose 4B according to the manufac-
turer’s instructions (Amersham Pharmacia Biotech). Approximately
15 Wmol of the peptide was coupled to 1 g dried Sepharose resin.
Myc-tagged SOCS-1 and CIS in pcDNA3 were transiently expressed
in 293T cells grown in 10-cm dishes. Cells were lysed in the above lysis
bu¡er containing 10% glycerol. Cell extracts were incubated with 20
Wl (50% v/v) of peptide-conjugated Sepharose, then washed three
times with lysis bu¡er, and analyzed by immunoblotting with anti-
Myc (9E10).
3. Results and discussion
3.1. Reconstitution of TCR signaling pathway in 293 T cells
It was shown that CD8/j chimeric protein consisting of the
extracellular and transmembrane domains of CD8 and the
cytoplasmic domain of the CD3j chain is capable of trans-
ducing signals in T cell lines in the absence of the CD3Q, N,
and O chains [13]. To reconstitute the TCR signaling pathway
in 239T cells, we ¢rst transfected a construct of CD8/j chi-
meric protein together with a variety of constructs of PTKs
including Lck, Syk, ZAP70, and Tec in 293T cells, and tyro-
sine phosphorylation of CD8/j was examined after precipita-
tion with anti-CD8 mAb. As shown in Fig. 1A, CD8/j was
tyrosine-phosphorylated by each individual PTK examined. In
addition, tyrosine-phosphorylated PTKs except Tec were co-
precipitated with CD8/j. Although Lck is a prerequisite for
activation of ZAP70 in T cells [2], co-expression of Lck with
Syk or ZAP70 did not enhance phosphorylation of CD8/j.
To investigate whether the phosphorylation of CD8/j indu-
ces NF-AT activation in 293T cells, we then transfected both
NF-ATc and NF-AT luciferase constructs [14] together with
CD8/j and each individual PTK construct into 293T cells, and
the NF-AT luciferase activity was assayed. As shown in Fig.
1B, the expression of Syk and CD8/j induced a marked acti-
Fig. 2. Activation of PLC-Q1 and calcineurin pathway by Syk and CD8/j. A^C: 293T cells in 10-cm dishes were transfected with Syk (5 Wg)
and CD8/j (10 Wg). After 48 h, they were lysed and immunoprecipitated with anti-PLC-Q1 (A), anti-Cbl (B), and anti-Vav (C). The immunopre-
cipitate with each antibody was probed with an anti-phosphotyrosine antibody as indicated (anti-PY, upper panel). The blot was stripped and
reprobed with the respective antibody (lower panel). Molecular weight markers on the left are in kilodaltons. (D) NF-AT activation mediated
by CD8/j and Syk in 293T cells can be blocked by CsA or FK506. 293T cells transfected with CD8/j and Syk were cultured in the presence
or absence of the indicated concentrations of CsA or FK506. 48 h after transfection, cells were harvested and luciferase activity was deter-
mined. The results shown here are representative of at least three independent experiments.
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vation of NF-AT, whereas expression of other PTKs and
CD8/j showed no or very little e¡ect on the activation. Si-
multaneous expression of CD8/j and Syk was a prerequisite
for the NF-AT activation in 293T cells (Fig. 1C). This ¢nding
is in accordance with those of previous studies showing that
Syk enhances TCR-mediated NF-AT activation and IL-2 pro-
duction [15^17]. It is possible that the combination of Lck
with ZAP70 could not transduce the signals due to the lack
of T cell-speci¢c adapter molecules, such as SLP-76 [2].
3.2. Involvement of the endogenous PLC-Q1 and calcineurin
pathway in the reconstituted TCR signaling cascade in
293T
When CD8/j and Syk were co-expressed in 293T cells, var-
ious tyrosine-phosphorylated substrates other than CD8/j and
Syk were observed (Fig. 1A), which implies that Syk might act
by directly tyrosine-phosphorylating downstream substrates
such as PLC-Q1, Cbl or Vav [2]. To verify this possibility,
CD8/j and Syk constructs were co-transfected into 293T cells,
and tyrosine phosphorylation of the substrates was examined
after immunoprecipitations. As shown in Fig. 2A, a strong
phosphorylation of the endogenous PLC-Q1 was induced by
CD8/j and Syk in 293T cells. Although a previous paper
showed that Syk also phosphorylated the cytosolic Cbl in
transiently transfected COS-1 cells [4], we could not detect
tyrosine phosphorylation of either Cbl or Vav in the trans-
fected 293T cells (Fig. 2B,C). These results suggest that en-
dogenous PLC-Q1 plays a pivotal role in the NF-AT activa-
tion induced by CD8/j and Syk in 293T cells.
We then examined the e¡ect of the immunosuppressive
drugs CsA and FK506, which are known as potent inhibitors
of TCR-mediated IL-2 gene expression, on the induction of
NF-AT activation by CD8/j and Syk in 293T cells. As shown
in Fig. 2D, both drugs inhibited the CD8/j- and Syk-induced
NF-AT activation in a dose-dependent fashion, suggesting
that this transcriptional response of NF-AT in 293T cells is
mediated by the calcineurin pathway [3].
3.3. E¡ects of additional PTKs on CD8/j- and Syk-mediated
NF-AT activation
In order to examine the e¡ect of other PTKs on CD8/j-
and Syk-mediated NF-AT activation, Lck or Tec was co-ex-
pressed together with CD8/j and Syk in 293T cells, and NF-
AT activity was assessed. As shown in Fig. 3A, an additional
expression of Lck resulted in the decrease in NF-AT activa-
tion in a dose-dependent manner. This inhibitory e¡ect may
be due to the activation of endogenous protein tyrosine phos-
phatases, like SHP-2 [18]. In fact, overexpression of SHP-2
partially inhibited NF-AT activation induced by CD8/j and
Syk (data not shown). In contrast, an additional expression of
Tec markedly augmented CD8/j- and Syk-mediated NF-AT
activation (Fig. 3B). These results support previous data dem-
onstrating that Btk/Tec and Syk family kinases exert distinct
e¡ects on calcium signaling [19,20]. These results also suggest
that this novel system is useful to identify regulatory mole-
cules which are involved in NF-AT activation triggered by
CD3j and Syk.
3.4. Inhibition of CD8/j- and Syk-mediated NF-AT activation
by SOCS-1
Previous studies suggested that SOCS family proteins, neg-
ative regulatory molecules for cytokine signals, may play some
roles in T cell development [8,9]. To investigate the e¡ect of
the SOCS family proteins on Syk-dependent NF-AT activa-
tion in 293T cells, we co-expressed SOCS-1, CIS, or SOCS-3
together with CD8/j and Syk, and the luciferase activity in
293T cells was determined. Expression of SOCS-1 inhibited
the NF-AT activation in a dose-dependent fashion, while CIS
expression had little e¡ect on the activation (Fig. 4A). SOCS-3
had a moderate inhibitory e¡ect on the activation. We further
examined their e¡ect on tyrosine phosphorylation of CD8/j.
Both SOCS-1 and SOCS-3 reduced tyrosine phosphorylation
of CD8/j, while CIS showed little e¡ect on the phosphory-
lation (Fig. 4B). Furthermore, when SOCS-1 or CIS was ex-
pressed together with CD8/j and Syk, SOCS-1, but not CIS,
was co-precipitated with Syk as well as CD8/j (Fig. 4C). In
the absence of Syk, SOCS-1 was not co-precipitated with
CD8/j (data not shown), suggesting that SOCS-1 directly
bound to tyrosine-phosphorylated CD8/j via their ITAMs.
To determine whether SOCS-1 directly interacts with the
ITAMs of the j chain, SOCS-1 or CIS expressed in 293T cells
was incubated with ITAM peptide-conjugated Sepharose
beads, and the ability to bind to these peptides was examined.
As shown in Fig. 4D, SOCS-1, but not CIS, showed binding
ability to the phosphorylated ITAMs. It bound to either
ITAM peptides singly phosphorylated at each tyrosine residue
(P1 or P2) or ones doubly phosphorylated (P1, P2), but not to
the unphosphorylated peptides. These results show that
SOCS-1 acts as a negative regulator for the CD8/j- and
Syk-mediated NF-AT activation by directly binding to the
ITAM(s) of the j chain.
3.5. Concluding remarks
The present report describes a novel system to explore
ITAM-mediated NF-AT activation. This novel system may
be useful for exploring the regulatory molecule(s) downstream
of CD3j or Syk. Using this system, we demonstrated that
SOCS-1 inhibited this CD8/j- and Syk-induced NF-AT acti-
vation by directly binding to Syk and ITAM present at the j
chain. Although the role of the SOCS family in vivo has not
Fig. 3. E¡ects of other PTKs on CD8/j- and Syk-mediated NF-AT
activation. 293T cells in 6-cm dishes were transfected with increasing
amounts of Lck (A) or Tec (B) and CD8/j, Syk, NF-ATc, NF-AT-
Luc and L-gal. 48 h after transfection, cells were harvested and lu-
ciferase activity was determined. The results shown here are repre-
sentative of at least three independent experiments.
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Fig. 4. SOCS-1 inhibits Syk-mediated NF-AT activation and binds to the phosphorylated ITAMs. A: 293T cells in 6-cm dishes were trans-
fected with increasing amounts of Myc-tagged SOCS-1, CIS or SOCS-3 together with CD8/j, Syk, NF-ATc, NF-AT-Luc, and L-gal. 48 h after
transfection, cells were harvested and luciferase activity was determined. The results shown here are representative of at least three independent
experiments. B: 293T cells in 10-cm dishes were transfected with increasing amounts of Myc-tagged SOCS-1, CIS or SOCS-3 together with
CD8/j (10 Wg) and Syk (5 Wg) by the calcium precipitation method. 48 h after transfection, cells were lysed and CD8/j was immunoprecipitated
with anti-CD8 mAb. Phosphotyrosine-containing proteins were detected by immunoblotting with the anti-phosphotyrosine antibody 4G10
(upper panel). The blot was stripped and reprobed with anti-CD3j (middle panel). Expression of Myc-tagged proteins was detected by immu-
noblotting with anti-Myc (lower panel). Molecular weight markers on the left are in kilodaltons. C: 293T cells were transfected with Myc-
tagged SOCS-1 (10 Wg) or CIS (10 Wg) together with CD8/j (10 Wg) and Syk (5 Wg) by the calcium precipitation method. 48 h after transfec-
tion, cells were lysed and immunoprecipitated with anti-Myc, anti-CD8, and anti-Syk. Myc-tagged proteins were detected by immunoblotting
with anti-Myc (upper panel). The blot was stripped and reprobed with each antibody (lower panel). Molecular weight markers on the left are
in kilodaltons. D: The sequences of phosphorylated and unphosphorylated ITAMs used are shown above. The beads conjugated with the indi-
cated peptides were incubated with 293T cell lysate expressing Myc-tagged SOCS-1 and Myc-tagged CIS. After washing, beads were subjected
to SDS^PAGE and blotted with anti-Myc. The input Myc-tagged proteins are shown on the right.
FEBS 23579 20-4-00
T. Matsuda et al./FEBS Letters 472 (2000) 235^240 239
yet been clearly determined, our results indicate that SOCS-1
may be involved in the TCR-mediated NF-AT signaling path-
way.
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